Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CLEO Diagnostics Ltd ( (AU:COV) ) just unveiled an announcement.
Hudson Institute Investment Holdings Pty Ltd has lodged a regulatory notice stating it has ceased to be a substantial holder in CLEO Diagnostics Limited, meaning its relevant interest in the company’s voting securities has fallen below the substantial holding threshold. The change in holding, formalised in early January 2026, may modestly alter CLEO Diagnostics’ share register composition and reduce the influence of this former major investor, but the filing is procedural in nature and does not in itself signal any disclosed change to the company’s operations or strategic direction.
The most recent analyst rating on (AU:COV) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on CLEO Diagnostics Ltd stock, see the AU:COV Stock Forecast page.
More about CLEO Diagnostics Ltd
CLEO Diagnostics Limited is an Australian-listed company, identified by ACN 655 717 169. While this notice does not describe its operations, CLEO Diagnostics operates within the medical diagnostics sector, focusing on developing and commercialising diagnostic technologies, with its securities traded on the local equity market.
Average Trading Volume: 250,683
Technical Sentiment Signal: Buy
Current Market Cap: A$79.03M
See more insights into COV stock on TipRanks’ Stock Analysis page.